Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription 05.01.2026 1 AJR Am J Roentgenol 2 Am J Clin Oncol 1 Am J Surg 4 Ann Oncol 3 Ann Surg Oncol 8 Anticancer Res 6 BMC Cancer 2 BMJ 1 BMJ Oncol 1 Br J Cancer 2 Breast Cancer 1 Breast Cancer (Auckl) 10 Breast Cancer (Dove Med Press) 16 Breast Cancer Res 5 Breast Cancer Res Treat 5 Breast J 1 Cancer 1 Cancer Epidemiol Biomarkers Prev 2 Cancer Lett 5 Clin Breast Cancer 1 Clin Cancer Res 1 Clin Med Insights Oncol 1 Eur J Cancer 1 Eur J Surg Oncol 2 Eur Radiol 2 Int J Oncol 1 Int J Radiat Oncol Biol Phys 1 J Biol Chem 1 J Clin Invest 1 J Natl Cancer Inst 1 J Surg Oncol 2 Lancet Oncol 4 NPJ Breast Cancer 1 Oncogene 1 Oncol Rep 4 PLoS One 1 Radiology 2 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. DESAI C
   Another Instrument to Improve Breast Cancer Outcomes.
   AJR Am J Roentgenol. 2025 Dec 24. doi: 10.2214/AJR.25.34386.
   PubMed        
   
   

   
   Am J Clin Oncol

2. QURESHI Z, Jamil A, Samsuddoha K, Kahlon N, et al
   Dual Inhibition of HER2 and VEGF Pathways in Breast Cancer: A Meta-analysis of Outcomes.
   Am J Clin Oncol. 2025 Dec 29. doi: 10.1097/COC.0000000000001293.
   PubMed         Abstract available
   
   
3. LOTZ M, Keates S, Carr D, Noor N, et al
   Overactive Bladder Symptoms in Cancer Patients Undergoing Chemotherapy.
   Am J Clin Oncol. 2026;49:25-29.
   PubMed         Abstract available
   
   

   
   Am J Surg

4. TANG A, Schulz-Costello K, Jones V, Tseng J, et al
   Germline pathogenic variants in Asian American/Pacific Islander women with breast cancer.
   Am J Surg. 2025;253:116786.
   PubMed         Abstract available
   
   

   
   Ann Oncol

5. PISTILLI B, Jhaveri K, Im SA, Pernas S, et al
   Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study.
   Ann Oncol. 2025 Dec 23:S0923-7534(25)06337-9. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
6. ARORA A, Bhaskarane H, Tansir G, Bakhshi S, et al
   A Phase II, Randomized, open-label study to evaluate low-dose Pembrolizumab plus Chemotherapy vs Chemotherapy as Neoadjuvant Therapy for localized Triple Negative Breast Cancer (TNBC). [PLANeT Trial - Pembrolizumab Low Dose in Addition to NACT in TNBC
   Ann Oncol. 2025 Dec 22:S0923-7534(25)06335-5. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
7. GLUZ O, Kates R, Kuemmel S, Nitz U, et al
   A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding "Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer" by Chen et al.
   Ann Oncol. 2025 Dec 20:S0923-7534(25)06333-1. doi: 10.1016/j.annonc.2025.
   PubMed        
   
   
8. SCHMID PS, McArthur HL, Cortes J, Xu B, et al
   Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial.
   Ann Oncol. 2025 Dec 19:S0923-7534(25)06332-X. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

9. VETTER C, Day CN, Habermann EB, Boughey JC, et al
   Differences in Breast Cancer Care Between Rural Women Undergoing Treatment at a Referral Center and Those Treated Locally.
   Ann Surg Oncol. 2025 Dec 29. doi: 10.1245/s10434-025-18812.
   PubMed         Abstract available
   
   
10. BARMETTLER G, Kantor O
    ASO Author Reflections: Identifying Differences in Treatment Patterns in Sexual and Gender Minorities with Breast Cancer.
    Ann Surg Oncol. 2025 Dec 27. doi: 10.1245/s10434-025-18964.
    PubMed        
    
    
11. VETTER C, Day CN, Habermann EB, Boughey JC, et al
    ASO Visual Abstract: Differences in Breast Cancer Care Between Rural Women Undergoing Treatment at a Referral Center Compared with Those Treated Locally.
    Ann Surg Oncol. 2025 Dec 24. doi: 10.1245/s10434-025-18920.
    PubMed        
    
    

    
    Anticancer Res

12. CHANG CJ, Tung SL, Liao WT, Lay IS, et al
    THEMIS2 as a Novel Mediator of VEGFR2-driven Angiogenesis in Breast Cancer: Functional Suppression by miR-125b-5p.
    Anticancer Res. 2026;46:95-111.
    PubMed         Abstract available
    
    
13. GOTO W, Kashiwagi S, Nishikawa M, Watanabe C, et al
    Radiological Complete Response as a Prognostic Marker in HR-positive Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: Implications for Treatment De-escalation.
    Anticancer Res. 2026;46:319-325.
    PubMed         Abstract available
    
    
14. KINOSHITA H, Kashiwagi S, Nishikawa M, Watanabe C, et al
    Efficacy and Safety of Subcutaneous Pertuzumab-Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan.
    Anticancer Res. 2026;46:293-300.
    PubMed         Abstract available
    
    
15. SUWAN N, Teerawongsuwan S, Jenjittikul S, Senaweenin Y, et al
    Andrographolide Induces Mitochondrial Dysfunction and Alters Stemness-related Gene Expression in MCF7 Breast Cancer Cells.
    Anticancer Res. 2026;46:263-272.
    PubMed         Abstract available
    
    
16. SUGINO Y, Sakurada H, Baba M, Saito Y, et al
    Risk Factor Analysis for Bevacizumab-induced Severe Hypertension in Advanced Breast Cancer Treatment.
    Anticancer Res. 2026;46:385-394.
    PubMed         Abstract available
    
    
17. AL DARWASHI LM, Hajeir MY, Abdelrahman RM, Nordahl EJ, et al
    Efficacy of Magseed Localization for Non-palpable Breast Lesions: A Systematic Review and Meta-analysis.
    Anticancer Res. 2026;46:1-14.
    PubMed         Abstract available
    
    
18. MATSUDA H, Goto W, Henmi S, Nishikawa M, et al
    Real-world Outcomes of Postoperative Management for Sentinel Lymph Node-positive Breast Cancer Without Intraoperative Assessment: A Single-institution Retrospective Study.
    Anticancer Res. 2026;46:429-437.
    PubMed         Abstract available
    
    
19. HENMI S, Kashiwagi S, Matsuda H, Nishikawa M, et al
    Clinical-Genomic Risk Discordance in Early HR+/HER2- Breast Cancer: A Real-World Cohort from Japan Demonstrates Treatment Impact of Oncotype DX.
    Anticancer Res. 2026;46:439-446.
    PubMed         Abstract available
    
    

    
    BMC Cancer

20. LV M, Liu Y, Cao W, Wang Y, et al
    Identification of RPGRIP1L as an instability-maintaining gene to drive tumor growth and PD-L1 expression via Hedgehog signaling in breast cancer.
    BMC Cancer. 2025 Dec 30. doi: 10.1186/s12885-025-15500.
    PubMed         Abstract available
    
    
21. NAFISSI N, Rezazadeh M, Kheradpishe A, Radkhah H, et al
    Diagnostic value of peripheral blood inflammatory indices for breast cancer grade and immunohistochemical markers: a retrospective observational study.
    BMC Cancer. 2025;25:1886.
    PubMed         Abstract available
    
    
22. WEI C, Zhou S, Zhu L, Kong J, et al
    Comparison of the efficacy between radiotherapy alone and surgery plus radiotherapy for ipsilateral supraclavicular lymph node metastasis in breast cancer based on propensity score matching analysis: a retrospective study with 8-year follow-up.
    BMC Cancer. 2025 Dec 26. doi: 10.1186/s12885-025-15424.
    PubMed        
    
    
23. CHEN BA, Qin WH, Chen HB, Yang QH, et al
    The effect of exercise intervention on IGF axis and metabolic markers regulation in breast cancer patients: a systematic review with pairwise, network, and dose-response meta-analyses.
    BMC Cancer. 2025 Dec 26. doi: 10.1186/s12885-025-15475.
    PubMed        
    
    
24. MASHAYEKH Z, Fard RF, Vallian S
    Noncoding RNAs and DNA methylation as epigenetic modulators of breast cancer: mechanisms and clinical perspectives in the Iranian population, a systematic review.
    BMC Cancer. 2025 Dec 20. doi: 10.1186/s12885-025-15430.
    PubMed        
    
    
25. WU F, Xu F, He J, Hu H, et al
    Reducing breast biopsy at MRI: comparison of minimum ADC cutoff and mean ADC cutoff identified by the ECOG-ACRIN A6702 multicenter trial.
    BMC Cancer. 2025;25:1938.
    PubMed         Abstract available
    
    

    
    BMJ

26. PETRELLI F
    Adjuvant carboplatin for high risk triple negative breast cancer.
    BMJ. 2025;391:r2669.
    PubMed        
    
    
27. LIU Y, Gong Y, Zhu XZ, Liu GY, et al
    Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.
    BMJ. 2025;391:e085457.
    PubMed         Abstract available
    
    

    
    BMJ Oncol

28. QUTOB IA, Soliman A, Aufy H, Elgahamy AS, et al
    Breast cancer awareness and breast self-examination among females in the Middle East and North Africa: a multinational cross-sectional study.
    BMJ Oncol. 2025;4:e000869.
    PubMed         Abstract available
    
    

    
    Br J Cancer

29. DE SOUZA WAGNER PH, Matheus GTFU, Monteiro Ribeiro D, Figueroa Magalhaes MC, et al
    Breast cancer incidence and subtype patterns among BRCA-mutated ovarian cancer patients: a systematic review and meta-analysis.
    Br J Cancer. 2025 Dec 23. doi: 10.1038/s41416-025-03320.
    PubMed         Abstract available
    
    

    
    Breast Cancer

30. KUSAMA H, Horimoto Y, Adachi K, Koyama Y, et al
    Bridging across the pacific: overview of the 33rd annual meeting of the Japanese breast cancer society.
    Breast Cancer. 2025 Dec 29. doi: 10.1007/s12282-025-01811.
    PubMed         Abstract available
    
    
31. LIN SM, Ku HY, Shiau JP, Chen FM, et al
    Long-term outcomes of adjuvant radiation in elderly Asians with early stage IIA breast cancer after breast-conserving surgery: a population-based study.
    Breast Cancer. 2025 Dec 22. doi: 10.1007/s12282-025-01810.
    PubMed        
    
    

    
    Breast Cancer (Auckl)

32. IAMPENKHAE K, Pisutpunya A, Vuthithammee C, Sodsoon P, et al
    Comparative Analysis of Equivocal (2+) and Positive (3+) HER2 Immunohistochemistry (IHC) and Bright-Field Dual-Color In Situ Hybridization (DISH) in Primary Breast Cancer From 1,307 Node-Positive Patients.
    Breast Cancer (Auckl). 2025;19:11782234251407914.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

33. HUANG X, Lin S, Lin R, Luo S, et al
    Inavolisib-Based Therapy for PIK3CA-Mutated Advanced Male Breast Cancer: A Cost-Effectiveness Analysis.
    Breast Cancer (Dove Med Press). 2025;17:1385-1396.
    PubMed         Abstract available
    
    
34. XU L, Xu H, Jiang D, Song S, et al
    Neuregulin-1 Secreted by Cancer-Associated Fibroblasts Promotes Growth of Triple-Negative Breast Cancer.
    Breast Cancer (Dove Med Press). 2025;17:1413-1425.
    PubMed         Abstract available
    
    
35. XUE D, Hou R, Xu H, Li X, et al
    Down-Regulation of lncRNA CKMT2-AS1 Predicts Poor Prognosis and Promotes Breast Cancer Progression.
    Breast Cancer (Dove Med Press). 2025;17:1397-1411.
    PubMed         Abstract available
    
    
36. CAO J, Qiao E, Shao H, Wang C, et al
    Differential TGF-beta1/SMAD4 Signaling Regulates PMN-MDSC Differentiation and Reshapes the Immune Microenvironment in Breast Cancer.
    Breast Cancer (Dove Med Press). 2025;17:1369-1383.
    PubMed         Abstract available
    
    
37. LIN X, Li X, Wei Q, Yuan H, et al
    Exploratory Research of Intraductal Chemotherapy to Control the Focal Breast Lesion of Breast Cancer.
    Breast Cancer (Dove Med Press). 2025;17:1321-1339.
    PubMed         Abstract available
    
    
38. GU M, Xia Y, Qian J, Shao C, et al
    Dexmedetomidine Suppresses Mitochondrial Autophagy and Apoptosis While Promoting Proliferation in Breast Cancer Cells in vitro via PI3K/AKT Signaling.
    Breast Cancer (Dove Med Press). 2025;17:1265-1278.
    PubMed         Abstract available
    
    
39. POGODA K, Pawlik H, Balata A, Czopowicz M, et al
    Management Strategies and Outcomes in HR+/HER2- Metastatic Breast Cancer Receiving CDK4/6 Inhibitors and Subsequent Therapies.
    Breast Cancer (Dove Med Press). 2025;17:1307-1319.
    PubMed         Abstract available
    
    
40. SHI A, An Y, Yun F, Liu X, et al
    IDO1, IL4I1: Novel Immune Checkpoints in Breast Cancer Tumor-Associated Macrophages.
    Breast Cancer (Dove Med Press). 2025;17:1279-1292.
    PubMed         Abstract available
    
    
41. ZHU M, Cheng R, Zhang K, Yue C, et al
    Clinical Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte Index (CALLY) in Patients with Stage III Breast Cancer.
    Breast Cancer (Dove Med Press). 2025;17:1293-1305.
    PubMed         Abstract available
    
    
42. CHEN G, Zhang K, Wang Y, Zhang Z, et al
    Mendelian Randomization Integrating GWAS and eQTL Data Reveals DAAM1, a Potential Immune-Related Biomarker for Breast Cancer Prognosis.
    Breast Cancer (Dove Med Press). 2025;17:1247-1263.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

43. COLLIN LJ, Woolpert KM, Kjaersgaard A, Ahern TP, et al
    17beta-Hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark.
    Breast Cancer Res. 2025 Dec 30. doi: 10.1186/s13058-025-02196.
    PubMed         Abstract available
    
    
44. YU HH, Gracia D, Chao TC, Ho CH, et al
    Survival analysis of adjuvant endocrine therapy in HER2 positive early breast cancer patients with low ER positivity.
    Breast Cancer Res. 2025;27:222.
    PubMed         Abstract available
    
    
45. ELKUM N, Al-Zahrani AS, Alraouji NN, Al-Tweigeri T, et al
    Obesity is a major modifiable factor associated with ER-negative breast cancer: epidemiological and mechanistic evidence from a high-risk cohort.
    Breast Cancer Res. 2025 Dec 29. doi: 10.1186/s13058-025-02189.
    PubMed        
    
    
46. TSENG LM, Huang CC, Chen JL, Tsai YF, et al
    Circulating T-cell receptor repertoire and clinicopathological correlations in breast cancer patients: immune repertoire analysis from the VGH-TAYLOR study.
    Breast Cancer Res. 2025;27:221.
    PubMed         Abstract available
    
    
47. KHAN Y, Verhaeghe N, Monten C, Vanthomme K, et al
    Subtype-specific health and economic impact of delayed breast cancer diagnosis during the early COVID-19 pandemic in Belgium: a Markov model analysis.
    Breast Cancer Res. 2025 Dec 28. doi: 10.1186/s13058-025-02207.
    PubMed        
    
    
48. REEVES G, Pirie K, Floud S, Black J, et al
    The aetiology of breast cancer subtypes: results from the Million Women Study.
    Breast Cancer Res. 2025 Dec 28. doi: 10.1186/s13058-025-02197.
    PubMed         Abstract available
    
    
49. PANG J, Chen Y, Wang H, Tang Y, et al
    Unleashing the potential role of tumor-associated NK cells as a novel immunotherapeutic target in triple-negative breast cancer.
    Breast Cancer Res. 2025 Dec 26. doi: 10.1186/s13058-025-02182.
    PubMed        
    
    
50. GRAM IT, Park SY, Wilkens LR, Haiman CA, et al
    Childhood exposure to second-hand smoke (SHS) and risk of breast cancer in postmenopausal never smokers: the Multiethnic Cohort (MEC) study.
    Breast Cancer Res. 2025 Dec 25. doi: 10.1186/s13058-025-02202.
    PubMed        
    
    
51. GU J, Qi Q, Mao X, Cong R, et al
    Integrated transcriptome study reveals a stress response state CD4 +T cells related to immune tolerance in breast cancer.
    Breast Cancer Res. 2025 Dec 24. doi: 10.1186/s13058-025-02205.
    PubMed        
    
    
52. MOIR N, Pearce DA, Langdon SP, Simpson TI, et al
    The significance of molecular heterogeneity in breast cancer batch correction and dataset integration.
    Breast Cancer Res. 2025;27:219.
    PubMed         Abstract available
    
    
53. DUTHEIL J, Pereira V, Boisson C, Mansi L, et al
    Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors.
    Breast Cancer Res. 2025;27:220.
    PubMed         Abstract available
    
    
54. CASTRESANA-AGUIRRE M, Matikas A, Lindstrom LS, Tobin NP, et al
    Computational decoding of cell-cycle phase effects on cancer hallmarks across breast cancer subtypes.
    Breast Cancer Res. 2025 Dec 24. doi: 10.1186/s13058-025-02208.
    PubMed        
    
    
55. FORMISANO L, Nappi L, Rosa R, Marciano R, et al
    Retraction Note: Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Breast Cancer Res. 2025;27:218.
    PubMed        
    
    
56. GUO L, Li J, Zhu W, Wang Z, et al
    PAK2 promotes CTC cluster formation by phosphorylating E-cadherin to enhance cell-cell adhesion in breast cancer.
    Breast Cancer Res. 2025 Dec 21. doi: 10.1186/s13058-025-02199.
    PubMed         Abstract available
    
    
57. BHAVE M, Jhaveri KL, Kaufman PA, Aftimos P, et al
    Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.
    Breast Cancer Res. 2025 Dec 21. doi: 10.1186/s13058-025-02168.
    PubMed        
    
    
58. CORREIA BF, Grosa D, Salvador R, Brites I, et al
    Neutrophils matter: new clinical insights on their role in the progression of metastatic breast cancer.
    Breast Cancer Res. 2025;27:223.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

59. CARSON EK, Dhillon HM, Vardy JL, Brown C, et al
    The impact of breast cancer treatment on sleep disturbance: a systematic review.
    Breast Cancer Res Treat. 2025;215:48.
    PubMed         Abstract available
    
    
60. OLOMU MUO, Scherer C, Wood E, Escobar K, et al
    Assessing barriers to genomic testing in breast cancer among diverse patients: a qualitative community-engaged research study.
    Breast Cancer Res Treat. 2025;215:47.
    PubMed         Abstract available
    
    
61. DUNN MR, Van Alsten SC, Emerson MA, Reeder-Hayes K, et al
    Tumor biology and access to care and metastatic breast cancer outcomes.
    Breast Cancer Res Treat. 2025;215:46.
    PubMed         Abstract available
    
    
62. DE PLACIDO P, Troll E, Niman SM, Ryan S, et al
    Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative database.
    Breast Cancer Res Treat. 2025;215:45.
    PubMed         Abstract available
    
    
63. WOPAT H, Patel R, Provenzano D, Rao YJ, et al
    Body composition, chemotherapy dosing and hematologic toxicity among Black and non-Black women being treated for breast cancer.
    Breast Cancer Res Treat. 2025;215:44.
    PubMed         Abstract available
    
    

    
    Breast J

64. ZHANG Y, He Y, Liu Q, Deng H, et al
    Predictive Value of Pyroptosis Markers (NLRP3, HMGB1, and Caspase-1) in the Prognosis of Patients With Metastatic Breast Cancer: A Prospective Observational Study.
    Breast J. 2025;2025:8821116.
    PubMed         Abstract available
    
    
65. SHANG F, Xu L, Liu H, Dong X, et al
    PMAIP1 Enhances DNA Damage and Induces ROS-Mediated Mitochondrial Dysfunction to Suppress Tumorigenesis in Triple-Negative Breast Cancer.
    Breast J. 2025;2025:7056712.
    PubMed         Abstract available
    
    
66. LI Z, Liu Y, Li Y, Shang Y, et al
    Fear of Cancer Recurrence Contributes Largely to Patient Anxiety and Depression and Quality of Life in a Prospective Cohort of Chinese Breast Cancer Patients for Postoperative Radiotherapy.
    Breast J. 2025;2025:5788053.
    PubMed         Abstract available
    
    
67. ATA B, Karadag V, Cetin K
    Effectiveness of Duct Excision Procedures in Detecting Preneoplastic and Malignant Lesions in Pathological Nipple Discharge: A Retrospective Cohort Study.
    Breast J. 2025;2025:2467046.
    PubMed         Abstract available
    
    
68. FABBRI MA, Fulvi A, Vergati M, D'Auria G, et al
    Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study.
    Breast J. 2025;2025:8976679.
    PubMed         Abstract available
    
    

    
    Cancer

69. CHOI HL, Kim B, Mark Park YM, Yoo JE, et al
    Metabolic obesity phenotypes and breast cancer risk before and after menopause: A nationwide cohort study in South Korea.
    Cancer. 2026;132:e70244.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

70. ZHANG Z, Ray RM, An R, Klonoff-Cohen HS, et al
    Mammographic Density as a Mediator for Breast Cancer Risk: Pooled Analysis of Four Population-Based Case-Control Studies on Women with Screening Mammograms Under 50.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Cancer Lett

71. LI J, Li Z, Zhang X, Zhang H, et al
    Histone lactylation bridges metabolic reprogramming with chromatin-immune crosstalk in triple-negative breast cancer.
    Cancer Lett. 2025;639:218227.
    PubMed         Abstract available
    
    
72. SAFAEI M, Li YC, Chen CY, Hsieh PH, et al
    Targeting ephrin receptor A10 with antibody-drug conjugates for breast cancer.
    Cancer Lett. 2025;639:218225.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

73. TURKEL A, Onur ID, Karakayali A, Alemdar MB, et al
    Survival Outcomes and Recurrence Patterns of Early-Stage HER2-Positive Breast Cancer Patients on Adjuvant T-DM1 Treatment: Turkish Oncology Group (TOG) Study.
    Clin Breast Cancer. 2025;26:131-138.
    PubMed         Abstract available
    
    
74. SAHBAZ PIRINCCI C, Gercek H, Cihan E, Durmaz ED, et al
    From Mobility to Management: A Scoping Review on Exercise in Breast Cancer-Related Lymphedema.
    Clin Breast Cancer. 2025;26:114-130.
    PubMed         Abstract available
    
    
75. DIELEMAN S, Kooreman LFS, Henkens MTHM, Hausen AZ, et al
    Histiocyte Quantity in Tumor-Negative Sentinel Lymph Nodes Predicts 10-Year Disease-Free Survival in Patients With Breast Cancer.
    Clin Breast Cancer. 2025 Dec 1:S1526-8209(25)00344.
    PubMed         Abstract available
    
    
76. YU X, Fan Y, Zhang S, Zhou L, et al
    Combined Compression and Exercise Therapy for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer: A Randomized Controlled Trial.
    Clin Breast Cancer. 2025;26:105-113.
    PubMed         Abstract available
    
    
77. JANNI W, Dent RA, Schmid P
    Rethinking First-Line Therapy and Beyond: HER2-Positive and Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer-Commentary Based on a Live Symposium Presented at the 2025 ESMO Congress in Berlin, Germany.
    Clin Breast Cancer. 2025;26:100-104.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

78. BIAGIONI C, Fimereli D, Irrthum A, Guerrero-Zotano A, et al
    Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01).
    Clin Cancer Res. 2025 Dec 22. doi: 10.1158/1078-0432.CCR-25-2707.
    PubMed         Abstract available
    
    

    
    Clin Med Insights Oncol

79. DHUNGANA R, Prasai P, Paudel B, Ranabhat K, et al
    Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Clin Med Insights Oncol. 2025;19:11795549251402955.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

80. DIECI MV, Vernaci G, Colangelo C, Bria E, et al
    PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world study.
    Eur J Cancer. 2025;234:116194.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

81. TSUJI W, Sasada S, Watanabe N, Tomita S, et al
    Effectiveness of post-mastectomy radiation therapy after breast reconstruction for patients with high-risk breast cancer: A retrospective multicenter cohort study (Reborn study-03).
    Eur J Surg Oncol. 2025;52:110523.
    PubMed         Abstract available
    
    

    
    Eur Radiol

82. RODRIGUEZ DE TRUJILLO CAMPO-CO, Romero-Martin S, Rodriguez-Alonso B, Font-Ugalde P, et al
    Predictive factors of axillary pathological complete response in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy.
    Eur Radiol. 2025 Dec 24. doi: 10.1007/s00330-025-12241.
    PubMed         Abstract available
    
    
83. VAN AMSTEL FJG, van Mierlo RGM, Nelemans PJ, Engelen SME, et al
    Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy.
    Eur Radiol. 2025 Dec 23. doi: 10.1007/s00330-025-12249.
    PubMed         Abstract available
    
    

    
    Int J Oncol

84. ZHANG N, Wang T, Bai B, Zhang X, et al
    PTPN18 functions as a tumor suppressor in breast cancer by negatively regulating cyclin E.
    Int J Oncol. 2026;68:30.
    PubMed         Abstract available
    
    
85. VIEDMA-RODRIGUEZ R, Baiza-Gutman LA, Garcia-Carranca A, Moreno-Fierros L, et al
    [Retracted] Suppression of the death gene BIK is a critical factor for resistance to tamoxifen in MCF?7 breast cancer cells.
    Int J Oncol. 2026;68:29.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

86. MENG J, Zhang L, Chen J, Shi W, et al
    A prospective phase II trial of hypofractionated stereotactic radiotherapy (FSRT) for patients with 1-10 brain metastases from breast cancer.
    Int J Radiat Oncol Biol Phys. 2025 Dec 24:S0360-3016(25)06606.
    PubMed         Abstract available
    
    

    
    J Biol Chem

87. NAGASATO-ICHIKAWA A, Murakami K, Aoki K, Okada M, et al
    The receptor tyrosine kinase ErbB2/HER2 governs CDK4 inhibitor sensitivity, timing, and irreversibility of the G1/S transition.
    J Biol Chem. 2025;301:110865.
    PubMed         Abstract available
    
    

    
    J Clin Invest

88. LI H, Zhang Y, Lin J, Zeng J, et al
    Tumor-derived neutrophil extracellular trap-associated DNA impairs treatment efficacy in breast cancer via CCDC25-dependent epithelial-mesenchymal transition.
    J Clin Invest. 2026;136:e190557.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

89. SHAO L, Wang Y, Shieh Y, Tamimi RM, et al
    Second primary cancer in breast cancer survivors by race/ethnicity and asian subgroups: a descriptive epidemiologic study.
    J Natl Cancer Inst. 2025 Dec 23:djaf372. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

90. HICKEY A, De la Cruz Ku G, King C, Franco C, et al
    Do Racial and Income Disparities Exist in the Application of 21-Gene Recurrence Score?
    J Surg Oncol. 2026;133:16-30.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

91. MONTAGNA G, Alvarado M, Myers S, Mrdutt MM, et al
    Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study.
    Lancet Oncol. 2026;27:57-67.
    PubMed         Abstract available
    
    
92. PATODIA S
    San Antonio Breast Cancer Symposium 2025.
    Lancet Oncol. 2025 Dec 18:S1470-2045(25)00753.
    PubMed        
    
    

    
    NPJ Breast Cancer

93. JILDERDA MF, Bartlett JMS, Liefers GJ, Zhang Y, et al
    Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer.
    NPJ Breast Cancer. 2025 Dec 30. doi: 10.1038/s41523-025-00885.
    PubMed         Abstract available
    
    
94. WU X, Jiang S, Ge A, Turman C, et al
    Investigating the relationship between breast cancer risk factors and an AI-generated mammographic texture feature in the Nurses' Health Study II.
    NPJ Breast Cancer. 2025 Dec 23. doi: 10.1038/s41523-025-00870.
    PubMed         Abstract available
    
    
95. SLEDGE GW, Xiu J, Mahtani RL, Sandoval Leon AC, et al
    Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling.
    NPJ Breast Cancer. 2025 Dec 20. doi: 10.1038/s41523-025-00868.
    PubMed         Abstract available
    
    
96. JERZAK KJ, Razis ED, Agostinetto E, Brastianos PK, et al
    Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases.
    NPJ Breast Cancer. 2025 Dec 20. doi: 10.1038/s41523-025-00856.
    PubMed         Abstract available
    
    

    
    Oncogene

97. ANDRIEU C, Stoof J, AlSultan D, Ivers L, et al
    Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patients.
    Oncogene. 2025 Dec 20. doi: 10.1038/s41388-025-03667.
    PubMed         Abstract available
    
    

    
    Oncol Rep

98. YEN MC, Shih YC, Hsu YL, Lin ES, et al
    [Corrigendum] Isolinderalactone enhances the inhibition of SOCS3 on STAT3 activity by decreasing miR?30c in breast cancer.
    Oncol Rep. 2026;55:36.
    PubMed         Abstract available
    
    

    
    PLoS One

99. FENG Y, Chen W, Lu Y, Zhou H, et al
    Correlation study of brain function changes after chemotherapy in breast cancer patients by automated fiber quantification based on diffusion tensor imaging.
    PLoS One. 2025;20:e0339924.
    PubMed         Abstract available
    
    
100. OEDINGEN C, Hua N, MacDonald KV, Marcadier J, et al
     To test or not to test? Study protocol for a best-worst scaling to understand decision-making and preferences for genetic testing in moderate-risk individuals.
     PLoS One. 2025;20:e0339696.
     PubMed         Abstract available
     
     
101. CEESAY I, Pwavodi PC, Shittu RO, Umar H, et al
     Green synthesis of zinc oxide nanoparticles using ethanolic leaf extract of Olea europaea and its in vitro evaluation on MDA-MB-231 cancer cell lines, antibacterial and antioxidant activities.
     PLoS One. 2025;20:e0339400.
     PubMed         Abstract available
     
     
102. SHENG Y, Fleming MR, Mezzanotte-Sharpe J, Hewavithana NS, et al
     A research protocol using ECG monitoring for detection of palpitations-associated arrhythmias in breast cancer survivors.
     PLoS One. 2025;20:e0338932.
     PubMed         Abstract available
     
     

     
     Radiology

103. ZHENG J, You C, Gu Y
     Capturing Treatment Dynamics: Multi-b-Value Diffusion-weighted Imaging to Advance Response Prediction in Breast Cancer Neoadjuvant Chemotherapy.
     Radiology. 2025;317:e252601.
     PubMed        
     
     

     
     Radiother Oncol

104. JAIKUNA T, Wilson F, Anandadas C, Azria D, et al
     Unveiling regions associated with acute and late breast side-effects from breast radiotherapy using voxel-wise image-based data mining analysis.
     Radiother Oncol. 2026;214:111230.
     PubMed         Abstract available
     
     
105. ATTILI A, Algranati C, Cianchetti M, Giacomelli I, et al
     A dedicated MKM-based radiobiological model for secondary cancer estimation in charged particle radiotherapy: An application in lymphomas and breast proton therapy.
     Radiother Oncol. 2026;214:111229.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.